Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells

Abstract

Aim: The purpose of this manuscript is to study the potential characteristics of acquired nutlin-3 resistant non-small cell lung cancer cells (NSCLC). Nutlin-3 is an inhibitor of the murine-double minute 2 protein, the main negative regulator of wild type p53, of which several derivatives are currently in clinical development.

Methods: A549 NSCLC cells were exposed to increasing concentrations of nutlin-3 for a period of 18 weeks. Monoclonal derivates were cultured, and the most resistance subclone was selected for whole transcriptome analysis. Gene set enrichment analysis was performed on differentially expressed genes between A549 nutlin-3 resistant cancer cells and the parental A549 p53 wild type cancer cells. Relevant findings were validated at the gene, protein and/or functional level.

Results: All nutlin-3 resistant subclones acquired mutations in the TP53 gene, resulting in overexpression of the mutant p53 protein. The most resistant subclone was enriched for genes related to epithelial to mesenchymal transition (EMT), resulting in increased migratory and invasive potential. Furthermore, these cells were enriched in genes related to inflammation, tissue remodelling, and angiogenesis. Importantly, expression of several immune checkpoints, including PD-L1 and PD-L2, was significantly upregulated, and cisplatin-induced cell death was reduced.

Conclusion: Transcriptome analysis of a highly nutlin-3 resistant A549 subclone shows the relevance of studying (1) resistance to standard of care chemotherapy; (2) secretion of immunomodulating chemo- and cytokines; (3) immune checkpoint expression; and (4) EMT and invasion in nutlin-3 resistant cancer cells in addition to acquired mutations in the TP53 gene.

Keywords

p53 / murine-double minute 2 / non-small cell lung cancer / acquired resistance / nutlin-3

References

[1] Deben C,Van Der Steen N.Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants..Tumour Biol2017;39:1010428317694327

[2] Deben C,Van den Bossche J.MDM2 SNP309 and SNP285 act as negative prognostic markers for non-small cell lung cancer adenocarcinoma patients..J Cancer2017;8:2154-62 PMCID:PMC5560132

[3] Deben C,Lardon F,Pauwels P.TP53 and MDM2 genetic alterations in non-small cell lung cancer: evaluating their prognostic and predictive value..Crit Rev Oncol Hematol2016;99:63-73

[4] Vassilev LT.Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics..Cell Cycle2004;3:419-21

[5] Deben C,Op de Beeck K.The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer..Oncotarget2015;6:22666-79 PMCID:PMC4673190

[6] Tisato V,Gonelli A,Zauli G.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer..J Hematol Oncol2017;10:133 PMCID:PMC5496368

[7] Pauwels B,de Pooter CM.Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies..Cancer Chemother Pharmacol2003;51:221-6

[8] Dobin A,Schlesinger F.STAR: ultrafast universal RNA-seq aligner..Bioinformatics2013;29:15-21 PMCID:PMC3530905

[9] Love MI,Anders S.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2..Genome Biol2014;15:550 PMCID:PMC4302049

[10] Liao Y,Jaehnig EJ,Zhang B.WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs..Nucleic Acids Res2019;47:W199-205 PMCID:PMC6602449

[11] Liberzon A,Thorvaldsdottir H,Mesirov JP.The molecular signatures database (MSigDB) hallmark gene set collection..Cell Syst2015;1:417-25 PMCID:PMC4707969

[12] Subramanian A,Mootha VK.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles..Proc Natl Acad Sci U S A2005;102:15545-50 PMCID:PMC1239896

[13] Vandeweyer G,Loeys B,Kooy RF.VariantDB: a flexible annotation and filtering portal for next generation sequencing data..Genome Med2014;6:74 PMCID:PMC4210545

[14] Soussi T,Hjortsberg L,Fournier JL.MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer..Hum Mutat2010;31:1020-5

[15] Pauwels B,Andriessen V.Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53..Radiat Res2005;164:642-50

[16] Wang MC,Cui J.BMI-1, a promising therapeutic target for human cancer..Oncol Lett2015;10:583-8 PMCID:PMC4509079

[17] Wu Z,Chen D.Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma..PLoS One2011;6:e14648 PMCID:PMC3032734

[18] Wang E,Szabolcs A.Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer..PLoS One2011;6:e17918 PMCID:PMC3061867

[19] Kucab JE,Arlt VM.Nutlin-3a selects for cells harbouring TP53 mutations..Int J Cancer2017;140:877-87 PMCID:PMC5215675

[20] Michaelis M,Barth S.Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells..Cell Death Dis2011;2:e243 PMCID:PMC3252738

[21] Aziz MH,Maki CG.Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3..Oncogene2011;30:4678-86 PMCID:PMC3347888

[22] Skalniak L,Polak J.Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells..Cancers (Basel)2018;10: PMCID:PMC6266412

[23] Lambert JM,Veprintsev DB.PRIMA-1 reactivates mutant p53 by covalent binding to the core domain..Cancer Cell2009;15:376-88

[24] Zhang Q,Wiman KG.APR-246 reactivates mutant p53 by targeting cysteines 124 and 277..Cell Death Dis2018;9:439 PMCID:PMC5906465

[25] Liu DS,Haupt S.Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation..Nat Commun2017;8:14844 PMCID:PMC5379068

[26] Bai X,Hou X,Jin J.Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters..Drug Metab Rev2016;48:541-67

[27] Stetler-Stevenson WG.Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention..J Clin Invest1999;103:1237-41 PMCID:PMC408361

[28] Page-McCaw A,Werb Z.Matrix metalloproteinases and the regulation of tissue remodelling..Nat Rev Mol Cell Biol2007;8:221-33 PMCID:PMC2760082

[29] Manegold C,Gray JE.The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC..J Thorac Oncol2017;12:194-207

[30] Yan H,Huang X.Role of interleukin-32 in cancer biology..Oncol Lett2018;16:41-7 PMCID:PMC6006503

[31] Kobayashi W.The epithelial-mesenchymal transition induced by transcription factor LEF-1 is independent of β-catenin..Biochem Biophys Rep2018;15:13-8 PMCID:PMC6038150

[32] Son H.Epithelial-mesenchymal transition and cell invasion..Toxicol Res2010;26:245-52 PMCID:PMC3834497

[33] Santiago L,Wang D,Lee P.Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment..Am J Cancer Res2017;7:1389-406 PMCID:PMC5489786